Updated:
Zoetis Inc
Zoetis is the world's leading animal health company with a nearly 75-year legacy in veterinary pharmaceuticals and diagnostics.
Zoetis Inc
Zoetis was established from Pfizer's animal health division in 1952, and spun off as a standalone public company in 2013. The firm is headquartered in Florham Park, New Jersey, with additional offices in Salt Lake City, Utah. Zoetis invests heavily in R&D targeting predictive, preventive, and therapeutic products across species including dogs, cats, horses, cattle, poultry, pigs, fish, and sheep. Its portfolio spans medicines, vaccines, diagnostics, biopharmaceuticals, and digital tools—like AI-powered diagnostic platforms. Key products include Librela and Solensia for pets, and Draxxin KP for livestock. The firm operates in over 100 countries. Zoetis employs a global team of scientists, veterinarians, and producers. In March 2026, the Zoetis Foundation reported $35 million in grant funding over its first five years, supporting veterinary professionals and farmers (per Zoetis, March 2026). The company has been named one of America's Best Employers by Forbes five consecutive years. As a public company listed on the NYSE, Zoetis does not operate as a family office or asset manager. Its structural differentiator is its singular focus on animal health, vertically integrating science, manufacturing, and commercial distribution across species and geographies—a breadth unmatched in the sector.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Florham Park
Corporate office
Florham Park, NJ, United States
Additional offices
Salt Lake City, UT, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Zoetis?
Zoetis is a publicly traded company led by its executive management team and board of directors. Investment decisions are made by corporate officers and senior leadership, not by a family office or external allocator. The firm's governance follows public-company standards.
How does Zoetis source proprietary deal flow?
Zoetis does not operate as an investment firm; it is a product-driven animal health company. Its R&D pipeline is built through internal discovery and development, as well as strategic acquisitions and partnerships in pharmaceuticals, vaccines, and diagnostics.
Is Zoetis structured as a single family office or does it operate more like a venture firm?
Neither. Zoetis is a publicly traded corporation (NYSE: ZTS) focused on animal health products and services. It does not manage outside capital or function as an asset manager.
Does Zoetis participate in fund commitments or only direct deals?
Zoetis does not participate in fund commitments. As an operating company, it engages in corporate development activities such as acquisitions and licensing, not as an LP in investment funds.
What investment stages does Zoetis typically target?
Zoetis does not target investment stages. It focuses on developing and commercializing animal health products across all stages of the product lifecycle, from early-stage R&D through mature marketed products.
Which sectors does Zoetis explicitly avoid?
Zoetis is exclusively focused on animal health. It does not participate in human healthcare, financial services, real estate, or other non-animal-vertical sectors.
Where does the underlying wealth come from?
Zoetis is not a family office; its revenue comes from product sales in the animal health market. The company was spun off from Pfizer and is owned by public shareholders.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: